News

Intercept Pharma’s hopes of getting its non-alcoholic steatohepatitis (NASH) therapy obeticholic acid (OCA) in the US may have

Intercept hit hard as NASH trial misses the mark

https://pharmaphorum.com/news/intercept-hit-hard-as-nash-trial-misses-the-mark/

News/ News/ Sales and Marketing

Supreme court throws Novartis a lifeline for Gilenya defense

Phil Taylor generic, Gilenya, HEC Pharma, litigation, multiple sclerosis, Novartis, patent, patent litigation 0 Comment

In a dramatic change in fortunes, Novartis has won a major victory in its bid to defend oral

Supreme court throws Novartis a lifeline for Gilenya defense

https://pharmaphorum.com/news/supreme-court-throws-novartis-a-lifeline-for-gilenya-defense/

Digital/ News/ News/ News/ Sales and Marketing

Babylon hires Andrew Hine to spearhead overseas expansion

Phil Taylor Babylon Health, digital, digital health, online consultation, senior management 0 Comment

UK digital health company Babylon has hired Andrew Hine to take charge of its international expansion efforts, as

Babylon hires Andrew Hine to spearhead overseas expansion

https://pharmaphorum.com/news/babylon-hires-andrew-hine-to-spearhead-overseas-expansion/

News/ News/ Sales and Marketing

Merck defends blockbuster Januvia franchise from patent challenge

Phil Taylor Diabetes, generic, Januvia, Merck & Co, Sales and Marketing, Viatris 0 Comment

Merck & Co has been fighting to defend its blockbuster type 2 diabetes therapy Januvia from generic competition

Merck defends blockbuster Januvia franchise from patent challenge

https://pharmaphorum.com/news/merck-defends-blockbuster-januvia-franchise-from-patent-challenge/

Market Access/ News/ News

Relief for Amylyx as FDA clears controversial ALS drug Relyvrio

Phil Taylor Amylyx, amyotrophic lateral sclerosis, fda, motor neuron disease, neurology, regulatory approval, Relyvrio 0 Comment

Patient organisations have been celebrating the FDA approval yesterday of Amylyx’ amyotrophic lateral sclerosis (ALS) therapy Relyvrio, after

Relief for Amylyx as FDA clears controversial ALS drug Relyvrio

https://pharmaphorum.com/news/relief-for-amylyx-as-fda-clears-controversial-als-drug-relyvrio/

News/ News/ R&D

Novo Nordisk grabs NASH drug from Ventus in $703m deal

Phil Taylor hepatology, Immunology and inflammation, licensing, NASH, NLRP3, Novo Nordisk, Ventus Therapeutics 0 Comment

Denmark’s Novo Nordisk has agreed to pay $70 million to license rights to a drug developed by Ventus

Novo Nordisk grabs NASH drug from Ventus in $703m deal

https://pharmaphorum.com/news/novo-nordisk-grabs-nash-drug-from-ventus-in-703m-deal/

Disease Spotlight/ DMD Main/ News/ News/ R&D

Sarepta files Duchenne muscular dystrophy gene therapy with FDA

Phil Taylor accelerated approval, DMD, Duchenne muscular dystrophy, Sarepta 0 Comment

Sarepta Therapeutics has followed through on its promise to file for accelerated approval of its gene therapy SRP-9001

Sarepta files Duchenne muscular dystrophy gene therapy with FDA

https://pharmaphorum.com/news/sarepta-files-duchenne-muscular-dystrophy-gene-therapy-with-fda/

News/ News/ R&D

Almirall joins IL-2 push in autoimmunity with $507m Simcere deal

Phil Taylor Almirall, autoimmune disease, cytokine therapies, dermatology, licensing, Simcere Pharmaceutical 0 Comment

Almirall has licensed an interleukin-2 (IL-2) drug from China’s Simcere Pharma, joining the ranks of companies looking at

Almirall joins IL-2 push in autoimmunity with $507m Simcere deal

https://pharmaphorum.com/news/almirall-joins-il-2-push-in-autoimmunity-with-507m-simcere-deal/

Market Access/ News/ News/ Press Releases

Name change for Johnson & Johnson offshoot to Kenvue

Nicole Raleigh consumer health, Johnson & Johnson, Kenvue, name change, rebranding, self-care 0 Comment

Trusted Johnson & Johnson brands including Tylenol, Aveeno, Neutrogena, Listerine, and Band-Aid are set to fall under the

Name change for Johnson & Johnson offshoot to Kenvue

https://pharmaphorum.com/news/name-change-for-johnson-johnson-offshoot-to-kenvue/

1 2 3 4 ›»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Trending

News

Login